Get the Stockscreener App
3.19
0.62%
-0.02
Envveno Medical Corporation stock is traded at $3.19, with a volume of 129.55K.
It is down -0.62% in the last 24 hours and down -3.92% over the past month.
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
See More
Previous Close:
$3.21
Open:
$3.3
24h Volume:
129.55K
Relative Volume:
0.94
Market Cap:
$57.34M
Revenue:
-
Net Income/Loss:
$-24.05M
P/E Ratio:
-1.4241
EPS:
-2.24
Net Cash Flow:
$-17.78M
1W Performance:
-5.34%
1M Performance:
-3.92%
6M Performance:
-36.33%
1Y Performance:
-16.71%
1-Day Range:
$3.10
$3.39
1-Week Range:
$3.10
$3.44
52-Week Range:
$3.012
$6.97
Envveno Medical Corporation Stock (NVNO) Company Profile
Name
Envveno Medical Corporation
Sector
Industry
Phone
949-261-2900
Address
70 DOPPLER, IRVINE
Compare NVNO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVNO
Envveno Medical Corporation
|
3.19 | 57.34M | 0 | -24.05M | -17.78M | -2.24 |
|
ABT
Abbott Laboratories
|
118.95 | 208.18B | 41.22B | 5.77B | 6.49B | 2.94 |
|
SYK
Stryker Corp
|
388.14 | 148.70B | 21.97B | 3.59B | 3.21B | 6.74 |
|
BSX
Boston Scientific Corp
|
90.75 | 133.32B | 15.91B | 1.79B | 1.89B | 0.82 |
|
MDT
Medtronic Plc
|
86.27 | 111.27B | 33.00B | 4.29B | 5.50B | 2.71 |
|
EW
Edwards Lifesciences Corp
|
72.07 | 42.66B | 6.60B | 4.16B | 490.10M | 2.34 |
Envveno Medical Corporation Stock (NVNO) Latest News
enVVeno launches recap website highlighting VEITH Symposium participation - TipRanks
enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website - The Olympian
enVVeno Medical Showcases Breakthrough VenoValve Trial Data at VEITH Symposium | NVNO Stock News - StockTitan
NVNO Completes Application for VenoValve's PMA, Shares Likely to Gain - MSN
enVVeno Medical (NASDAQ:NVNO) Is In A Good Position To Deliver On Growth Plans - Simply Wall St
Reviewing enVVeno Medical (NASDAQ:NVNO) and Cerus (NASDAQ:CERS) - Defense World
PMA application submitted for VenoValve device - Venous News
enVVeno Medical (STU:5HJ) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
enVVeno Medical rises on submission of the venovalve PMA application for FDA approval - MSN
One-year data from the VenoValve US pivotal trial emerge - Venous News
enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium - AccessWire
enVVeno Medical's VenoValve Trial Shows 85% Success Rate in Pivotal Study | NVNO Stock News - StockTitan
enVVeno Medical seeks FDA approval for VenoValve - Investing.com India
enVVeno Medical seeks FDA approval for VenoValve By Investing.com - Investing.com Canada
enVVeno Medical submits VenoValve PMA application to FDA - TipRanks
enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval - AccessWire
enVVeno Medical Submits Final FDA Module for VenoValve Breakthrough Device | NVNO Stock News - StockTitan
Deep Venous Disease Treatment Devices Market 2024-2031 - openPR
Perceptive Advisors LLC's Strategic Acquisition in enVVeno Medical Corp - GuruFocus.com
enVVeno Medical (FRA:5HJ) Cyclically Adjusted FCF per Share : €0.00 (As of Jun. 2024) - GuruFocus.com
enVVeno Medical expects capital to fund company through several milestones - TipRanks
enVVeno Medical reports Q3 EPS (35c) vs. (45c) last year - TipRanks
enVVeno Medical Reports Third Quarter 2024 Financial Results and Confirms Guidance for Release of Definitive VenoValve Data in November and Completion of FDA Premarket Approval Application for VenoValve in Q4 of this Year - AccessWire
EnVVeno Medical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
enVVeno Medical initiates six-month pre-clinical GLP study of enVVe - TipRanks
enVVeno Medical Successfully Initiates 6-Month Pre-Clinical GLP Study Evaluating enVVe(R) - AccessWire
Comparing enVVeno Medical (NASDAQ:NVNO) and Accuray (NASDAQ:ARAY) - Defense World
NVNO Stock Hits 52-Week Low at $3.06 Amid Market Challenges - Investing.com UK
Contrasting enVVeno Medical (NASDAQ:NVNO) and Lucid Diagnostics (NASDAQ:LUCD) - Defense World
Do investors need to be concerned about enVVeno Medical Corporation (NVNO)? - US Post News
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session - MSN
NVNO: A Tale of Ups & Downs – -40.44% loss in 6 Months, -38.98% in 30 Days - The InvestChronicle
Market Resilience: enVVeno Medical Corporation (NVNO) Finishes Weak at 3.24, Down -28.00 - The Dwinnex
United States shares mixed at close of trade; Dow Jones Industrial Average up 0.33% - MSN
NVNO stock touches 52-week low at $3.4 amid market challenges - Investing.com
U.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.33% - MSN
enVVeno Medical stock falls after it prices $15M securities offering - MSN
NVNOenVVeno Medical Corporation Latest Stock News & Market Updates - StockTitan
EnVVeno Medical Announces Pricing Of Public OfferingQuick Facts - Nasdaq
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday - Benzinga
enVVeno Medical launches public stock offering By Investing.com - Investing.com Australia
enVVeno Medical Corporation Announces Pricing of $15.0 Million Public Offering - StockTitan
enVVeno Medical launches public stock offering - Investing.com India
enVVeno Medical offers to sell common stock - MSN
enVVeno Medical Corporation Announces Proposed Public Offering - AccessWire
Envveno Medical Corporation Stock (NVNO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):